DXO Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the near-haploid human HAP1 cell line, designed for targeted disruption of the DXO (decapping exoribonuclease) gene. This loss-of-function model enables detailed investigation of DXO’s role in mRNA cap quality control and surveillance pathways without the complications of diploid gene redundancy. The polyclonal format provides a genetically diverse knockout background, suitable for functional genomics screens and pathway analysis where population-level effects are desired. This product serves as a versatile tool for exploring the molecular mechanisms underlying aberrant mRNA decapping and degradation, as well as their implications in neurodevelopmental disorders.
The HAP1 cell line originates from KBM-7 chronic myeloid leukemia cells and is characterized by a haploid karyotype for most chromosomes, with disomy restricted to chromosome 8. This near-haploid state simplifies loss-of-function studies, as a single gene copy facilitates efficient CRISPR/Cas9-mediated disruption and robust phenotypic readouts. HAP1 cells are widely adopted for genetic screening, drug target validation, and mechanistic studies due to their ease of culture and broad utility across RNA biology, signal transduction, and cancer research. Their haploid nature is particularly advantageous for studying genes involved in essential processes such as RNA quality control, where complete knockout in diploid cells may be masked by functional complementation from the remaining allele.
DXO functions as a decapping exoribonuclease that specifically recognizes and removes aberrant 5′ caps from mRNA, including incompletely methylated, oxidized, or NAD-modified caps (nicotinamide adenine dinucleotide caps). Following decapping, DXO employs its intrinsic 5′-3′ exonuclease activity to degrade the unprotected RNA body, thereby preventing translation of faulty transcripts. This activity places DXO at the intersection of cap quality control and mRNA decay pathways. DXO is regulated upstream by the presence of defective mRNA caps generated under conditions of oxidative stress or by impaired RNA cap methyltransferase (RNMT) activity, and it interacts with multiple co-factors such as decapping complex subunits DCP1A and DCP2, the 5′-3′ exonuclease XRN1, and cap-binding proteins NCBP1 and EIF4E. Dysregulation of DXO-mediated surveillance leads to accumulation of 5′-monophosphorylated RNAs and aberrantly capped mRNA fragments, disrupting proteostasis and contributing to neurodevelopmental pathologies.
In the context of the HAP1 cell background, DXO knockout provides a clean, defined system for dissecting the mechanisms of mRNA cap quality control and its impact on global transcript stability. Loss of DXO in these haploid cells enables unambiguous assessment of defective cap handling, altered mRNA half-lives, and downstream effects on gene expression without interference from a second functional allele. This model is particularly relevant for studying intellectual developmental disorder and other neurodevelopmental conditions, where DXO mutations have been implicated. Researchers can employ this system to characterize the functional interplay between DXO and the broader mRNA surveillance machinery, including RNA exosome components and the UPF1/SMG6-mediated nonsense-mediated decay pathway, within a genetically tractable host.
This knockout product supports a wide range of experimental approaches essential for RNA biology and disease modeling. Applications include functional genomics of mRNA quality control, investigation of cap homeostasis under normal and stress conditions, and drug target validation for RNA metabolism disorders. Representative assays compatible with this model are Western blotting for DXO protein loss confirmation, RT-qPCR of DXO target mRNAs, actinomycin D chase experiments to measure RNA stability, cap immunoprecipitation to profile capped transcript populations, immunofluorescence for subcellular localization, RNA sequencing for whole-transcriptome analysis, 5′ end sequencing (CAGE) to assess cap status, and mRNA decay reporter assays. For further technical information or assistance, please contact Ascent Research.
